Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Ken Heimlich"'
Autor:
Sung Chul Kim, Anthony V. Lemmo, Cameron Olbert, Min Hyo Seo, Chris McNulty, Hongming Chen, Hun Seung Oh, Jang Won Lee, Ken Heimlich, Stephen J. Ellis, Zhong Zhang, Hye Jeong Yoon
Publikováno v:
Pharmaceutical Research. 20:1302-1308
Purpose. The purpose of this work was to replace Cremophor-EL in the commercial paclitaxel intravenous formulation, Taxol®, using a novel high-throughput combinatorial formulation approach. Methods. Full factorial combinations of 12 generally regard
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::883ae9626cd92503b4e23810d766b73c
https://doi.org/10.1023/a:1025021603288
https://doi.org/10.1023/a:1025021603288
Autor:
Hongming, Chen, Zhong, Zhang, Chris, McNulty, Cameron, Olbert, Hye Jeong, Yoon, Jang Won, Lee, Sung Chul, Kim, Min Hyo, Seo, Hun Seung, Oh, Anthony V, Lemmo, Stephen J, Ellis, Ken, Heimlich
Publikováno v:
Pharmaceutical research. 20(8)
The purpose of this work was to replace Cremophor-EL in the commercial paclitaxel intravenous formulation, Taxol, using a novel high-throughput combinatorial formulation approach.Full factorial combinations of 12 generally regarded as safe excipients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::831a7f67efdf4dd94e22f4423b4ff1e0
https://pubmed.ncbi.nlm.nih.gov/12948029
https://pubmed.ncbi.nlm.nih.gov/12948029
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 08/08/2023.
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 11/09/2022.
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 11/03/2021.
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 11/02/2020.
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 04/13/2020.
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 12/05/2019.
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 08/07/2019.
Autor:
Mattson-Teig, Beth
Publikováno v:
Wealth Management Real Estate. 2022 2nd Quarter, p32-37. 6p.